Congenital Fibrinogen Deficiency
3
Pipeline Programs
2
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
OctapharmaAustria - Vienna
4 programs1
2
OctafibrinPhase 31 trial
OctafibrinPhase 31 trial
OctafibrinPhase 21 trial
FibrygaN/A1 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
OctapharmaOctafibrin
OctapharmaOctafibrin
OctapharmaOctafibrin
OctapharmaFibryga
CSL BehringFCH
Clinical Trials (5)
Total enrollment: 91 patients across 5 trials
Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency
Start: Dec 2015Est. completion: Jun 201915 patients
Phase 3Completed
Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
Start: Sep 2014Est. completion: Feb 201825 patients
Phase 3Completed
Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap
Start: Jun 2013Est. completion: Jan 201522 patients
Phase 2Completed
Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
Start: Jan 2021Est. completion: May 20257 patients
N/ATerminated
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency
Start: May 2015Est. completion: Dec 201722 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space